OHSU launches gene therapy trial for AMD

Article

Portland, OR-Researchers in the Casey Eye Institute at Oregon Health & Science University (OHSU) began participation in February in a gene therapy trial for patients with age-related macular degeneration (AMD).

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Subscribe Now!
Recent Videos
Annaiz Grimm, BS, a research scientist at Seattle Children's Research Institute.
Prerna Mewawalla, MD, medical director of Apheresis and a hematologist-oncologist in the Division of Hematology and Cellular Therapy at Allegheny Health Network, as well as an associate professor at the Drexel University College of Medicine.
Surbhi Sidana, MD, an assistant professor of medicine, bone marrow transplantation, and cellular therapy at Stanford
Related Content
study investigator Heather Gray-Edwards, DVM, PhD, assistant professor of genetic & cellular medicine at UMass Chan, and a member of the Horae Gene Therapy Center

Dual-Vector AAV Gene Therapy for GM2 Gangliosidosis Shows Promising Early Outcomes

Matt Hoffman
September 2nd 2025
Article
ImmunoLogic Episode 5

ImmunoLogic, Episode 5: "Tumor Infiltrators and Triumphs: The Evolution of TIL Therapy" With Michael T. Lotze, MD

Joseph A. Fraietta, PhD;Michael T. Lotze, MD;Noah Stansfield;Matt Hoffman
September 2nd 2025
Podcast
CGTLive®’s Weekly Rewind

CGTLive®’s Weekly Rewind – August 29, 2025

Noah Stansfield
September 2nd 2025
Article
Rajesh Pahwa, MD, director of the Parkinson’s Disease and Movement Disorder Center at the University of Kansas Medical Center

Cell Therapy in Parkinson Disease: Bemdaneprocel and What Lies Ahead

Rajesh Pahwa, MD;Marco Meglio
September 2nd 2025
Podcast
Around the Helix: Cell and Gene Therapy Company Updates – August 27, 2025

Around the Helix: Cell and Gene Therapy Company Updates – August 27, 2025

Noah Stansfield
September 2nd 2025
Article
Prerna Mewawalla, MD, the medical director of Apheresis and a hematologist-oncologist in the Division of Hematology and Cellular Therapy at Allegheny Health Network

Unmet Needs Following Early-Line CAR-T for R/R Multiple Myeloma

Prerna Mewawalla, MD;Noah Stansfield
September 2nd 2025
Article
© 2025 MJH Life Sciences

All rights reserved.